- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Braveheart Bio, Inc. GAAP EPS of -$0.51 misses by $0.07 | 1 | Seeking Alpha | ||
| Di | Braveheart Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Fr | Braveheart Bio, Inc.: Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 | 6 | GlobeNewswire (USA) | ||
| Fr | Braveheart Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10. | Braveheart Bio, Inc.: Braveheart Bio Announces Upcoming Presentations at the American Heart Association Scientific Sessions 2026 | 1 | GlobeNewswire (USA) | ||
| 01.10. | Stifel reiterates Buy on Braveheart Bio stock, $45 target | 3 | Investing.com | ||
| BRAVEHEART BIO Aktie jetzt für 0€ handeln | |||||
| 01.10. | Stifel bestätigt Kaufempfehlung für Braveheart Bio mit Kursziel von 45 US-Dollar | 1 | Investing.com Deutsch | ||
| 16.09. | Braveheart Bio, Inc.: Braveheart Bio to Participate in Stifel Cardiometabolic Forum | 2 | GlobeNewswire (USA) | ||
| 14.09. | Goldman Sachs reiterates Braveheart Bio stock buy rating at $48 | 3 | Investing.com | ||
| 14.09. | Goldman Sachs bestätigt Kaufempfehlung für Braveheart Bio Aktie bei 48 Dollar | 2 | Investing.com Deutsch | ||
| 10.09. | Braveheart Bio stellt auf Gesundheitskonferenz Doppelstrategie für Herzmedikament vor | 1 | Investing.com Deutsch | ||
| 08.09. | Braveheart Bio, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.09. | Braveheart Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Braveheart Bio, Inc.: Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update | 193 | GlobeNewswire (Europe) | Phase 3 LIONHEART-HCM Trial of BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (oHCM) Initiated Cash and Cash Equivalents of $122.8 Million as of June 30, 2026, or $527.3 Million After Giving... ► Artikel lesen | |
| 31.08. | Cantor Fitzgerald initiates Braveheart Bio stock with overweight rating | 1 | Investing.com | ||
| 31.08. | TD Cowen initiates Braveheart Bio stock with buy rating | 1 | Investing.com | ||
| 31.08. | TD Cowen stuft Braveheart Bio Aktie mit 'Buy' ein | 1 | Investing.com Deutsch | ||
| 31.08. | Jefferies initiates Braveheart Bio stock with buy on heart drug potential | 1 | Investing.com | ||
| 31.08. | Stifel initiates Braveheart Bio stock with buy rating on HCM drug | 2 | Investing.com | ||
| 31.08. | Jefferies stuft Braveheart Bio mit "Buy" ein - Kurspotenzial von 75 % dank Herzmedikament | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen BRAVEHEART BIO INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 19,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRAVEHEART BIO INC finden Sie auf Wallstreet Online.